Charles Schwab Investment Management Inc. Cuts Position in OPKO Health, Inc. (NASDAQ:OPK)

Charles Schwab Investment Management Inc. lowered its position in OPKO Health, Inc. (NASDAQ:OPK) by 17.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,497,406 shares of the biotechnology company’s stock after selling 714,949 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.51% of OPKO Health worth $5,141,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Y Intercept Hong Kong Ltd purchased a new position in OPKO Health in the fourth quarter valued at $102,000. Ieq Capital LLC purchased a new position in shares of OPKO Health in the 4th quarter valued at about $52,000. Capital Advisors Inc. OK acquired a new stake in shares of OPKO Health during the 4th quarter worth about $220,000. PFG Investments LLC raised its position in shares of OPKO Health by 9.4% during the 4th quarter. PFG Investments LLC now owns 1,160,885 shares of the biotechnology company’s stock worth $1,707,000 after acquiring an additional 99,795 shares in the last quarter. Finally, World Investment Advisors LLC purchased a new stake in OPKO Health during the third quarter worth approximately $61,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

OPK has been the topic of several recent analyst reports. Barrington Research reiterated an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a research note on Wednesday, March 12th. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a research report on Wednesday, March 19th. Finally, StockNews.com raised shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Monday, March 3rd.

OPKO Health Price Performance

Shares of NASDAQ OPK opened at $1.80 on Wednesday. The stock has a market cap of $1.21 billion, a P/E ratio of -9.47 and a beta of 1.70. OPKO Health, Inc. has a twelve month low of $0.99 and a twelve month high of $2.04. The stock has a 50 day moving average of $1.66 and a two-hundred day moving average of $1.58. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The firm had revenue of $183.60 million during the quarter, compared to analysts’ expectations of $155.42 million. On average, research analysts forecast that OPKO Health, Inc. will post -0.25 earnings per share for the current year.

Insider Activity

In related news, CEO Phillip Md Et Al Frost purchased 500,000 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was acquired at an average price of $1.48 per share, for a total transaction of $740,000.00. Following the completion of the purchase, the chief executive officer now directly owns 213,036,477 shares of the company’s stock, valued at $315,293,985.96. This trade represents a 0.24 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last three months, insiders acquired 964,971 shares of company stock valued at $1,493,692. Insiders own 47.26% of the company’s stock.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.